Navigation Links
Study examines medicare use for Mohs micrographic surgery and surgical excision for skin cancer
Date:4/16/2012

CHICAGO An analysis of Medicare beneficiaries suggests that surgical treatment for nonmelanoma skin cancer (NMSC) increased substantially from 2001 through 2006, primarily due to a doubling in the rate of Mohs micrographic surgery procedures, according to a report published in the April issue of Archives of Dermatology, a JAMA Network publication.

More than 3 million NMSCs are diagnosed each year in the United States and the variety of treatment options include surgical excision and Mohs micrographic surgery (MMS), which examines 100 percent of the surgical margin during the procedure. Surgical excision is effective for most primary basal cell carcinomas but cure rates are higher with MMS in patients with recurrent, infiltrative and high-risk anatomical site cancers, such as on the face, the authors write in their study background. But the authors note there is debate about the efficacy of surgical treatment (MMS vs surgical excision) for primary NMSC and the cost-efficacy of MMS.

Kate V. Viola, M.D., M.H.S., of the Albert Einstein College of Medicine, New York, and colleagues conducted a retrospective analysis of Medicare beneficiaries undergoing surgery (MMS vs surgical excision) to treat NMSC. A total of 26,931 patients with NMSC were surgically treated from 2001 through 2006 in the researchers' 5 percent sample of Medicare beneficiaries. Of the operations, 9,802 (36.4 percent) were MMS and 17,129 (63.6 percent) were surgical excisions.

During the study period, the rate of surgical excision increased slightly (1.8 vs 2.1 per 100 Medicare beneficiaries), while the rate of MMS doubled (0.75 vs 1.5 per 100 Medicare beneficiaries). Compared with surgical excision, MMS was more likely to be performed on lesions on the lip (60.1 percent vs 39.9 percent) and eyelid (57.2 percent vs 42.8 percent). Atlanta had the highest proportion of patients with NMSC treated with MMS (45.1 percent). The authors note that a higher proportion of M
'/>"/>

Contact: Karen Peart
karen.peart@yale.edu
203-432-1326
JAMA and Archives Journals
Source:Eurekalert

Page: 1 2

Related medicine news :

1. UT MD Anderson study finds cancer related pain often undertreated
2. Tattoos, Piercings Tied to Heavier Drinking in French Study
3. Surgery Rates Rising for Non-Melanoma Skin Cancer: Study
4. Dissolvable Heart Artery Stents Appear Safe in Study
5. Study identifies potential treatment for lethal childhood leukemia
6. Study recommends ways to evaluate end-of-life care in nursing homes
7. Mayo Clinic breast cancer study finds new type of mutation
8. Decision guide reduced uncertainty over breast cancer prevention, study finds
9. Study Probes How Sad Movies Make Viewers Happy
10. Single Boomers Struggling as They Age: Study
11. Gay Adults Rejected by Parents Have Worse Health, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... (PRWEB) May 05, 2015 Beverly Hills Cosmetic ... health and beauty products to be sold at the offices ... in Beverly Hills, and worldwide through an online store ... to fill the gap between dental care and beauty with ... beautiful and youthful,” says Dr. Glosman. , Dr. Glosman’s ...
(Date:5/5/2015)... New Jersey (PRWEB) May 05, 2015 ... has maintained its strong and secure credit rating of ... of Horizon BCBSNJ’s financials last week, the Wall Street ... adequacy” and “leading market position” in determining the rating ... of mind is one of our top priorities, so ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 ... ) filed on behalf of men who ... their use of prescription testosterone replacement therapies ... multidistrict litigation underway in U.S. District Court, ... documents dated May 1st, defendants AbbVie, Inc., ...
(Date:5/5/2015)... CT (PRWEB) May 05, 2015 Sunny skies ... Cove Island Park as nearly 400 runners and walkers participated ... Run,” raising nearly $35,000. , The 5K and ... awareness about Lyme disease and to raise funds for tick-borne ... event created by the recent merger of Lyme ...
(Date:5/5/2015)... May 05, 2015 In a April 25, ... The Herald-Times , the Missouri State Highway Patrol (MSHP) announced ... production or use for the second year in a row. ... the FBI, reported 1,469 incidents in 2014 alone, around 15% ... around 2% of the US Population calls Indiana home, according ...
Breaking Medicine News(10 mins):Health News:Beverly Hills Dentist Arthur Glosman Launches New Dental Health And Beauty Product Line 2Health News:Horizon Blue Cross Blue Shield of New Jersey Maintains “A” Credit Rating from Standard & Poor’s 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 2Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 3Health News:A Forever Recovery Releases New Information on the Epidemic Rise Of Methamphetamine Abuse in Midwest America 2
... form of childhood disease, study says , , WEDNESDAY, Jan. ... identified a subtype of T-lymphoblastic leukemia (T-ALL) in children ... , Approximately 20 percent of children with T-ALL ... others with the disease, and doctors had been unable ...
... a provider of enterprise case management solutions that streamline ... a new Lagan Human Services Call Center solution ... in North America. The new solution is an ... range of functions depending on the programs administered, from ...
... of Wisdom(TM) as Worldwide Symbol for Cervical Cancer ... Month in the United States, a coalition of ... and others is partnering with their European counterparts ... cervical cancer worldwide. The Pearl of Wisdom ...
... Program ReviewsSEATTLE, Jan. 14 MetaStar, Wisconsin,s ... guidelines and software from Milliman Care Guidelines ... medical care reviews throughout the state. ... Care Guidelines (R) suite, MetaStar now uses ...
... Heavily in Promotion to Capture Share in Mature ... ResourcesWALTHAM, Mass., Jan. 14 Decision Resources, one ... focusing on pharmaceutical and healthcare issues, finds that ... in Europe) will propel Roche to sixth position ...
... market test, Uno Chicago Grill(R) will offer its new, ... dining chain to offer a gluten-free pizza and received ... disease, which affects approximately one percent of the population. ... during the northeastern market test prompted the company to ...
Cached Medicine News:Health News:Hard-to-Treat Leukemia Cell Subtype Identified 2Health News:Lagan Unveils Human Services Call Center Solution for North America 2Health News:U.S. and European Advocacy Groups Launch United, Global Campaign to Prevent Cervical Cancer 2Health News:U.S. and European Advocacy Groups Launch United, Global Campaign to Prevent Cervical Cancer 3Health News:U.S. and European Advocacy Groups Launch United, Global Campaign to Prevent Cervical Cancer 4Health News:Milliman Care Guidelines(R) Replaces Multiple Guideline Sets for Wisconsin QIO 2Health News:Milliman Care Guidelines(R) Replaces Multiple Guideline Sets for Wisconsin QIO 3Health News:Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012 2Health News:Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012 3Health News:Uno Chicago Grill(R) Rolls Out Gluten-Free Pizza Nationally 2
(Date:5/5/2015)...  Trovagene, Inc. (NASDAQ:  TROV), a developer of ... for the three months ended March 31, 2015. ... presented favorable clinical results at ASCO GI, AACR, ... Precision Cancer Monitoring platform,s ability to detect and ... cancers," said Antonius Schuh, Ph.D., chief executive officer ...
(Date:5/5/2015)... NEW YORK , May 5, 2015  IBM ... it is collaborating with more than a dozen leading ... identify and personalize treatment options for their patients. The ... cognitive capabilities to reduce from weeks to minutes the ... profile and gather relevant information from medical literature to ...
(Date:5/5/2015)... , May 5, 2015 ... at $94.9 million in 2014, and is estimated to ... of 7.8% from 2014 to 2019. Browse ... Device Market for an analysis of industry trends and ... http://www.micromarketmonitor.com/market/north-america-glaucoma-surgery-devices-8830146604.html Early ...
Breaking Medicine Technology:Trovagene, Inc. Announces First Quarter 2015 Financial Results 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 4Trovagene, Inc. Announces First Quarter 2015 Financial Results 5Trovagene, Inc. Announces First Quarter 2015 Financial Results 6Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 2Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 3Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 4Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 5Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 6North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 2North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 3
... NEW YORK, Sept. 6, 2011 ... market research report is available ... Licensing Strategies of Large ... Pipelines and the Patent Cliff ...
... Global regenerative medicine company, Mesoblast Limited, (ASX: ... from the European Medicines Agency (EMA) to begin ... Europe for its lead cardiovascular product Revascor(TM) in ... heart failure after a major heart attack. Revascor(TM) ...
Cached Medicine Technology:Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 2Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 3Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 4Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 5Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 6Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 7Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 8Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 9Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 10Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 11Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 12Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 13Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 14Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 15Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 16Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or 'Off-The-Shelf' Stem Cell Treatment for Heart Attacks 2Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or 'Off-The-Shelf' Stem Cell Treatment for Heart Attacks 3Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or 'Off-The-Shelf' Stem Cell Treatment for Heart Attacks 4
Eye Bank Specular Microscope. Specular microscope for easy examination of corneal slice extracted from a donor....
... system uses prolene as thread-guide reducing time and ... Probe is inserted into the nasolacrimal duct and ... The probe is then withdrawn leaving the polypropylene ... diam silicone tubing into place. Newly coated with ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... conforms to natural anatomy of the ... on disposable inserter/dilator instrument for ease ... The Micro-Large plugs feature the unique ... shape of the eyelid. The slightly ...
Medicine Products: